Skip to search formSkip to main contentSkip to account menu

idraparinux

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligosaccharides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Application of the EF and GH Fragments to the Synthesis of Idraparinux.
A novel total synthesis of fully protected idraparinux has been achieved. A short and efficient protocol for the synthesis of the… 
2011
2011
The Antithrombotic Activity of EP224283, a Neutralizable Dual Factor Xa Inhibitor/Glycoprotein IIbIIIa Antagonist, Exceeds That of the Coadministered Parent Compounds
EP224283 combines in a single molecule idraparinux and tirofiban, which allows obtaining a predictable and sustained antiplatelet… 
2010
2010
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: A subgroup analysis of the Van Gogh DVT trial
Summary Standard treatment with heparin followed by vitamin K antagonists is frequently complicated by bleeding and recurrent… 
Review
2010
Review
2010
Novel anticoagulant therapy: principle and practice.
  • S. Mousa
  • Methods in molecular biology
  • 2010
  • Corpus ID: 24040893
Currently, there are several lines of evidence supporting the interplay between coagulation and inflammation in the propagation… 
Review
2009
Review
2009
From heparin to EP217609: The long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile
Summary The elucidation of the structure of the antithrombin binding sequence in heparin has given a large impulse to the… 
Review
2008
Review
2008
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders
Background: Idraparinux is a synthetic pentasaccharide that binds to antithrombin with high affinity. In view of its long half… 
Review
2007
Review
2007
Investigational treatments of venous thromboembolism
The antithrombotic management of venous thromboembolism (VTE) has gone through major developments. Indirect inhibitors such as… 
Review
2004
Review
2004
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
Traditional anticoagulants have drawbacks that make them complex to manage, limit their usefulness, and increase the possibility… 
Review
2003
Review
2003
Short‐ and long‐acting synthetic pentasaccharides
Abstract Koopman MMW, Büller HR (Academic Medical Centre, Amsterdam, The Netherlands). Short‐ and long‐acting synthetic… 
2003
2003
Idraparinux and liver enzymes: observations from the PERSIST trial
A potential influence of idraparinux – a synthetic analogue of the pentasaccharide sequence in heparins – on plasma liver enzyme… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)